C-reactive protein/albumin ratio as a prognostic biomarker in myasthenia gravis

Esen Çiçekli; Dilcan Kotan

Article Details

C-reactive protein/albumin ratio as a prognostic biomarker in myasthenia gravis

Authors:

Esen Çiçekli | Dilcan Kotan

Publisher:

MediHealth Academy Yayıncılık

Main Topics:

Nöroloji ve Nöromüsküler Hastalıklar

Journal:

Journal of Health Sciences and Medicine Vol.8 Issue 1, pp.126-131

Document Type:

Article

Publication Date:

12/2025

Document Language:

English

Document ID (Org No.):

2001338934

pISSN:

2636-8579

Keywords:

Abstract:

 Aims: Limited research has explored novel inflammatory targets in myasthenia gravis MG. This study aimed to investigate the role of the C-reactive protein CRPalbumin ratio CAR in disease activity and prognosis in MG patients. Methods: CRP, albumin, and CAR levels were compared between MG patients and healthy controls. The relationships of these parameters with MG activities of daily living MG-ADL scores and mortality were examined. Results: Sixty-six patients and 51 controls participated. CRP and CAR levels were significantly higher in the patient group p0.002, 0.003. No significant difference was found in albumin levels p0.154. A positive correlation was observed between the MG-ADL stage and both CRP and CAR levels p0.000 for both, with these markers increasing as MG-ADL worsened. A negative correlation was found between the MG-ADL stage and albumin p0.003. CRP, CAR, and albumin levels were significantly associated with mortality p0.000, 0.000, 0.005. Conclusion: Elevated CRP and CAR levels in MG patients suggest acute inflammation contributing to clinical decline. Albumins decrease with worsening MG-ADL suggests its value as a prognostic marker rather than a diagnostic. CAR proved to be a stronger marker than albumin for disease diagnosis, severity monitoring, and mortality prediction. Our findings could help illuminate inflammatory mechanisms in MG and other neuromuscular diseases.

 Aims: Limited research has explored novel inflammatory targets in myasthenia gravis MG. This study aimed to investigate the role of the C-reactive protein CRPalbumin ratio CAR in disease activity and prognosis in MG patients. Methods: CRP, albumin, and CAR levels were compared between MG patients and healthy controls. The relationships of these parameters with MG activities of daily living MG-ADL scores and mortality were examined. Results: Sixty-six patients and 51 controls participated. CRP and CAR levels were significantly higher in the patient group p0.002, 0.003. No significant difference was found in albumin levels p0.154. A positive correlation was observed between the MG-ADL stage and both CRP and CAR levels p0.000 for both, with these markers increasing as MG-ADL worsened. A negative correlation was found between the MG-ADL stage and albumin p0.003. CRP, CAR, and albumin levels were significantly associated with mortality p0.000, 0.000, 0.005. Conclusion: Elevated CRP and CAR levels in MG patients suggest acute inflammation contributing to clinical decline. Albumins decrease with worsening MG-ADL suggests its value as a prognostic marker rather than a diagnostic. CAR proved to be a stronger marker than albumin for disease diagnosis, severity monitoring, and mortality prediction. Our findings could help illuminate inflammatory mechanisms in MG and other neuromuscular diseases.

 Aims: Limited research has explored novel inflammatory targets in myasthenia gravis MG. This study aimed to investigate the role of the C-reactive protein CRPalbumin ratio CAR in disease activity and prognosis in MG patients. Methods: CRP, albumin, and CAR levels were compared between MG patients and healthy controls. The relationships of these parameters with MG activities of daily living MG-ADL scores and mortality were examined. Results: Sixty-six patients and 51 controls participated. CRP and CAR levels were significantly higher in the patient group p0.002, 0.003. No significant difference was found in albumin levels p0.154. A positive correlation was observed between the MG-ADL stage and both CRP and CAR levels p0.000 for both, with these markers increasing as MG-ADL worsened. A negative correlation was found between the MG-ADL stage and albumin p0.003. CRP, CAR, and albumin levels were significantly associated with mortality p0.000, 0.000, 0.005. Conclusion: Elevated CRP and CAR levels in MG patients suggest acute inflammation contributing to clinical decline. Albumins decrease with worsening MG-ADL suggests its value as a prognostic marker rather than a diagnostic. CAR proved to be a stronger marker than albumin for disease diagnosis, severity monitoring, and mortality prediction. Our findings could help illuminate inflammatory mechanisms in MG and other neuromuscular diseases.

 Amaçlar: Sınırlı sayıda araştırma, miyastenia graviste MG yeni inflamatuar hedefleri araştırmıştır. Bu çalışma, MG hastalarında hastalık aktivitesi ve prognozda C-reaktif protein CRPalbümin oranının CAR rolünü araştırmayı amaçlamıştır. Yöntemler: CRP, albümin ve CAR düzeyleri MG hastaları ile sağlıklı kontroller arasında karşılaştırılmıştır. Bu parametrelerin MG günlük yaşam aktiviteleri MG-ADL skorları ve mortalite ile ilişkileri incelenmiştir. Sonuçlar: Altmış altı hasta ve 51 kontrol katılmıştır. CRP ve CAR düzeyleri hasta grubunda anlamlı şekilde daha yüksekti p0,002, 0,003. Albümin düzeylerinde anlamlı bir fark bulunmamıştır p0,154. MG-ADL evresi ile hem CRP hem de CAR düzeyleri arasında pozitif bir korelasyon gözlenmiştir her ikisi için de p0,000, bu belirteçler MG-ADL kötüleştikçe artmıştır. MG-ADL evresi ile albümin arasında negatif bir korelasyon bulunmuştur p0,003. CRP, CAR ve albumin düzeyleri mortalite ile anlamlı şekilde ilişkiliydi p0,000, 0,000, 0,005. Sonuç: MG hastalarında yüksek CRP ve CAR düzeyleri, akut inflamasyonun klinik düşüşe katkıda bulunduğunu düşündürmektedir. Albüminin kötüleşen MG-ADL ile azalması, tanısal olmaktan çok prognostik bir belirteç olarak değerini düşündürmektedir. CAR, hastalık tanısı, şiddet takibi ve mortalite tahmini için albuminden daha güçlü bir belirteç olduğu kanıtlanmıştır. Bulgularımız, MG ve diğer nöromüsküler hastalıklardaki inflamatuar mekanizmaları aydınlatmaya yardımcı olabilir.

Article Details

C-reactive protein/albumin ratio as a prognostic biomarker in myasthenia gravis

Authors:

Esen Çiçekli | Dilcan Kotan

Publisher:

MediHealth Academy Yayıncılık

Main Topics:

Nöroloji ve Nöromüsküler Hastalıklar

Journal:

Journal of Health Sciences and Medicine Vol.8 Issue 1, pp.126-131

Document Type:

Article

Publication Date:

12/2025

Document Language:

English

Document ID (Org No.):

2001338934

pISSN:

2636-8579

Myasthenia gravis

C-reactive protein

albuminMyastenia gravis

C-reaktif protein

albumin

Issues

Article Details

C-reactive protein/albumin ratio as a prognostic biomarker in myasthenia gravis

Authors: Esen Çiçekli | Dilcan Kotan

Publisher: MediHealth Academy Yayıncılık

Main Topics: Nöroloji ve Nöromüsküler Hastalıklar

Journal: Journal of Health Sciences and Medicine Vol.8 Issue 1, pp.126-131

Document Type: Article

Publication Date: 12/2025

Document Language: English

Document ID (Org No.): 2001338934

pISSN: 2636-8579

Myasthenia gravis

C-reactive protein

albuminMyastenia gravis

C-reaktif protein

albumin

Issues

Authors:

Esen Çiçekli | Dilcan Kotan

Publisher:

MediHealth Academy Yayıncılık

Main Topics:

Nöroloji ve Nöromüsküler Hastalıklar

Journal:

Journal of Health Sciences and Medicine Vol.8 Issue 1, pp.126-131

Document Type:

Article

Publication Date:

12/2025

Document Language:

English

Document ID (Org No.):

2001338934

pISSN:

2636-8579